Cargando…
Targeting Trypanothione Reductase, a Key Enzyme in the Redox Trypanosomatid Metabolism, to Develop New Drugs against Leishmaniasis and Trypanosomiases
The protozoans Leishmania and Trypanosoma, belonging to the same Trypanosomatidae family, are the causative agents of Leishmaniasis, Chagas disease, and human African trypanosomiasis. Overall, these infections affect millions of people worldwide, posing a serious health issue as well as socio-econom...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221613/ https://www.ncbi.nlm.nih.gov/pubmed/32326257 http://dx.doi.org/10.3390/molecules25081924 |
_version_ | 1783533400884248576 |
---|---|
author | Battista, Theo Colotti, Gianni Ilari, Andrea Fiorillo, Annarita |
author_facet | Battista, Theo Colotti, Gianni Ilari, Andrea Fiorillo, Annarita |
author_sort | Battista, Theo |
collection | PubMed |
description | The protozoans Leishmania and Trypanosoma, belonging to the same Trypanosomatidae family, are the causative agents of Leishmaniasis, Chagas disease, and human African trypanosomiasis. Overall, these infections affect millions of people worldwide, posing a serious health issue as well as socio-economical concern. Current treatments are inadequate, mainly due to poor efficacy, toxicity, and emerging resistance; therefore, there is an urgent need for new drugs. Among several molecular targets proposed, trypanothione reductase (TR) is of particular interest for its critical role in controlling the parasite’s redox homeostasis and several classes of active compounds that inhibit TR have been proposed so far. This review provides a comprehensive overview of TR’s structural characterization. In particular, we discuss all the structural features of TR relevant for drug discovery, with a focus on the recent advances made in the understanding of inhibitor binding. The reported cases show how, on the basis of the detailed structural information provided by the crystallographic analysis, it is possible to rationally modify molecular scaffolds to improve their properties. |
format | Online Article Text |
id | pubmed-7221613 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72216132020-05-22 Targeting Trypanothione Reductase, a Key Enzyme in the Redox Trypanosomatid Metabolism, to Develop New Drugs against Leishmaniasis and Trypanosomiases Battista, Theo Colotti, Gianni Ilari, Andrea Fiorillo, Annarita Molecules Review The protozoans Leishmania and Trypanosoma, belonging to the same Trypanosomatidae family, are the causative agents of Leishmaniasis, Chagas disease, and human African trypanosomiasis. Overall, these infections affect millions of people worldwide, posing a serious health issue as well as socio-economical concern. Current treatments are inadequate, mainly due to poor efficacy, toxicity, and emerging resistance; therefore, there is an urgent need for new drugs. Among several molecular targets proposed, trypanothione reductase (TR) is of particular interest for its critical role in controlling the parasite’s redox homeostasis and several classes of active compounds that inhibit TR have been proposed so far. This review provides a comprehensive overview of TR’s structural characterization. In particular, we discuss all the structural features of TR relevant for drug discovery, with a focus on the recent advances made in the understanding of inhibitor binding. The reported cases show how, on the basis of the detailed structural information provided by the crystallographic analysis, it is possible to rationally modify molecular scaffolds to improve their properties. MDPI 2020-04-21 /pmc/articles/PMC7221613/ /pubmed/32326257 http://dx.doi.org/10.3390/molecules25081924 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Battista, Theo Colotti, Gianni Ilari, Andrea Fiorillo, Annarita Targeting Trypanothione Reductase, a Key Enzyme in the Redox Trypanosomatid Metabolism, to Develop New Drugs against Leishmaniasis and Trypanosomiases |
title | Targeting Trypanothione Reductase, a Key Enzyme in the Redox Trypanosomatid Metabolism, to Develop New Drugs against Leishmaniasis and Trypanosomiases |
title_full | Targeting Trypanothione Reductase, a Key Enzyme in the Redox Trypanosomatid Metabolism, to Develop New Drugs against Leishmaniasis and Trypanosomiases |
title_fullStr | Targeting Trypanothione Reductase, a Key Enzyme in the Redox Trypanosomatid Metabolism, to Develop New Drugs against Leishmaniasis and Trypanosomiases |
title_full_unstemmed | Targeting Trypanothione Reductase, a Key Enzyme in the Redox Trypanosomatid Metabolism, to Develop New Drugs against Leishmaniasis and Trypanosomiases |
title_short | Targeting Trypanothione Reductase, a Key Enzyme in the Redox Trypanosomatid Metabolism, to Develop New Drugs against Leishmaniasis and Trypanosomiases |
title_sort | targeting trypanothione reductase, a key enzyme in the redox trypanosomatid metabolism, to develop new drugs against leishmaniasis and trypanosomiases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221613/ https://www.ncbi.nlm.nih.gov/pubmed/32326257 http://dx.doi.org/10.3390/molecules25081924 |
work_keys_str_mv | AT battistatheo targetingtrypanothionereductaseakeyenzymeintheredoxtrypanosomatidmetabolismtodevelopnewdrugsagainstleishmaniasisandtrypanosomiases AT colottigianni targetingtrypanothionereductaseakeyenzymeintheredoxtrypanosomatidmetabolismtodevelopnewdrugsagainstleishmaniasisandtrypanosomiases AT ilariandrea targetingtrypanothionereductaseakeyenzymeintheredoxtrypanosomatidmetabolismtodevelopnewdrugsagainstleishmaniasisandtrypanosomiases AT fiorilloannarita targetingtrypanothionereductaseakeyenzymeintheredoxtrypanosomatidmetabolismtodevelopnewdrugsagainstleishmaniasisandtrypanosomiases |